Raymond Sanchez, M.D., has served as our Chief Medical Officer since January 2019.
Prior to joining us, Dr. Sanchez held various roles of increasing responsibility at Otsuka Pharmaceutical Development and Commercialization, Inc., where he most recently served as senior vice president, global clinical development. Previously, Dr. Sanchez served as the chief medical officer of Avanir Pharmaceuticals Inc. and held leadership roles at Bristol-Myers Squibb and Purdue Pharma.
Dr. Sanchez is currently the Executive Co-Chair of the International Society for CNS Drug Development (ISCDD), and a trustee and member of the board of directors of the Connecticut Mental Health Center Foundation, Yale School of Medicine, as well as several other not-for-profit organizations. In 2021, he was named as one of the ‘Top 100 Leaders in Healthcare’ by the International Forum on Advancements in Healthcare.
Dr. Sanchez received an A.B. from Northwestern University and an M.D. from the Feinberg School of Medicine at Northwestern University. He completed his residency training and fellowship in psychiatry at the Yale University Medical School, where he was appointed as an instructor.
What is Ramiro Sanchez's net worth?
The estimated net worth of Ramiro Sanchez is at least $659,698.08 as of December 26th, 2023. Dr. Sanchez owns 14,673 shares of Cerevel Therapeutics stock worth more than $659,698 as of November 17th. This net worth approximation does not reflect any other assets that Dr. Sanchez may own. Additionally, Dr. Sanchez receives a salary of $805,130.00 as Insider at Cerevel Therapeutics. Learn More about Ramiro Sanchez's net worth.
How old is Ramiro Sanchez?
Dr. Sanchez is currently 63 years old. There are 8 older executives and no younger executives at Cerevel Therapeutics. The oldest executive at Cerevel Therapeutics is Mr. Kenneth A. DiPietro, Chief Human Resources Officer, who is 65 years old. Learn More on Ramiro Sanchez's age.
What is Ramiro Sanchez's salary?
As the Insider of Cerevel Therapeutics Holdings, Inc., Dr. Sanchez earns $805,130.00 per year. The highest earning executive at Cerevel Therapeutics is Dr. N. Anthony Coles Jr., M.P.H., Executive Chairman, who commands a salary of $1,140,000.00 per year. Learn More on Ramiro Sanchez's salary.
How do I contact Ramiro Sanchez?
Has Ramiro Sanchez been buying or selling shares of Cerevel Therapeutics?
Ramiro Sanchez has not been actively trading shares of Cerevel Therapeutics during the last ninety days. Most recently, Ramiro Sanchez sold 10,000 shares of the business's stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $42.47, for a transaction totalling $424,700.00. Following the completion of the sale, the insider now directly owns 14,673 shares of the company's stock, valued at $623,162.31. Learn More on Ramiro Sanchez's trading history.
Who are Cerevel Therapeutics' active insiders?
Cerevel Therapeutics' insider roster includes Scott Akamine (Chief Legal Officer and Corporate Secretary), Susan Altschuller (CFO), Paul Burgess (Chief Business Development and Strategic Operations Officer), Anthony Coles (Director), Kenneth DiPietro (Insider), Deval Patrick (Director), Ronald Renaud, Jr. (CEO), John Renger (Insider), Ramiro Sanchez (Insider), and Gabrielle Sulzberger (Director). Learn More on Cerevel Therapeutics' active insiders.
Are insiders buying or selling shares of Cerevel Therapeutics?
In the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 236,864 shares worth more than $9,768,056.92. The most recent insider tranaction occured on July, 1st when Director N Anthony Coles sold 25,000 shares worth more than $1,029,500.00. Insiders at Cerevel Therapeutics own 5.1% of the company.
Learn More about insider trades at Cerevel Therapeutics. Information on this page was last updated on 7/1/2024.
